EMulate Therapeutics Announces Brett Greene, Veteran in the Psychedelic and Cannabinoid Biotechnology Industry, as a Company Advisor

Written By Kyle Kingma
Kyle Kingma
Previous

EMulate Therapeutics Announces the Publication of Its Phase I/II Results in CNS Oncology: “An Expanded Safety/Feasibility Study of the EMulate Therapeutics Voyager in Patients with Recurrent GBM”
Next

Magnetic field tech captures the ‘song’ of a drug